Skip to main content
. 2022 Aug 23;20(3):2693. doi: 10.18549/PharmPract.2022.3.2693

Table 1.

The demographic and clinical characteristics of the studied population, n=291

Cohort Pregabalin Gabapentin
N (%) 291 247 (85.0) 44 (15.0)
Female gender 178 (61.2) 149 (60.0) 29 (66.0)
Age Mean (±SD) 60.5 (13.0) 60.1 (12.7) 62.9 (13.4)
18-30 2 (0.8) 2 (0.8) -
31-40 5 (2.0) 5 (2.0) -
41-50 31 (10.7) 26 (10.5) 5 (11.4)
51-60 63 (21.6) 52 (21.0) 11 (25.0)
>60 190 (65.3) 162 (66.0) 28 (64.0)
Comorbidities
Cardiovascular diseases 230 (79.0) 191 (77.3) 39 (88.6.)
- Hypertension 137 (47.1) 113 (45.7) 24 (54.5)
- Dyslipidemia 62 (21.3) 52 (21.1) 10 (22.7)
- Ischemic heart disease 14 (4.8) 10 (4.0) 4 (9.1)
Endocrine 137 (47.1) 113 (45.7) 24 (54.5)
- Diabetes mellitus 124 (42.6) 104 (42.1) 20 (45.5)
- Thyroid diseases 11 (3.8) 7 (2.8) 4 (9.1)
Rheumatology 72 (24.7) 62 (21.3) 10 (22.7)
- Osteoporosis 21 (7.2) 16 (6.5) 5 (11.4)
- Osteoarthritis 17 (5.8) 15 (6.1) 2 (4.5)
- Rheumatoid arthritis 8 (3.2) 8 (3.2) -
Neurology 47 (16.4) 40 (16.2) 7 (15.9)
Orthopedic 40 (13.7) 35 (14.2) 5 (11.4)
Others 109 (37.4) 88 (35.6) 21 (47.4)
Setting
Outpatient 264 (91.0) 223 (90.0) 41 (93.0)
Prescription type (N = 216)
Follow up visit 116 (53.7) 96 (52.5) 20 (60.6)
Refill 97 (44.9) 84 (45.9) 13 (39.4)
New 3 (1.4) 3 (1.6) -
Prescriber’s specialty (N = 247)
Endocrinology 41 (16.6) 37 (17.6) 4 (10.8)
Family medicine 30 (12.1) 25 (11.9) 5 (13.5)
Medicine 28 (11.3) 24 (11.4) 4 (10.8)
Neurology 24 (9.7) 17 (8.1) 7 (18.9)
Hematology 21 (8.5) 19 (9.0) 2 (5.4)
Others 103 (41.7) 88 (41.9) 15 (40.5)
Prescriber’s rank (N = 174)
Consultant 57 (32.8) 49 (32.9) 8 (32.0)
Specialist 55 (31.6) 50 (33.6) 5 (20.0)
Resident 44 (25.3) 36 (24.2) 8 (32.0)
Intern/senior medical officer 18 (10.3) 14 (9.4) 4 (16.0)

Some data do not add up to 100% as some were missing